These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33830989)

  • 21. Report of combined therapy in leprosy with rifampicin and isoprodian conducted at the Bisidimo-center, Ethiopia.
    Rohde R
    Lepr Rev; 1975 Jun; 46(2 Suppl):199-205. PubMed ID: 1100961
    [No Abstract]   [Full Text] [Related]  

  • 22. Preliminary experience with rifampicin and isoprodian in combination in leprosy treatment.
    Krenzien HN
    Lepr Rev; 1975 Jun; 46(2 Suppl):189-98. PubMed ID: 1100960
    [No Abstract]   [Full Text] [Related]  

  • 23. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy.
    Soares DJ; Neupane K; Britton WJ
    Lepr Rev; 1995 Sep; 66(3):210-3. PubMed ID: 7500815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
    Ji B
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):391-2. PubMed ID: 9934368
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of leprosy with rifampicin and isoprodian in 38 patients at St. Thomas Hospital, Chetput, Sout India.
    Aschhoff M
    Lepr Rev; 1975 Jun; 46(2 Suppl):173-8. PubMed ID: 1165697
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to 'Elimination of leprosy in India: An analysis'.
    Kumar B
    Indian J Dermatol Venereol Leprol; 2018; 84(4):443-444. PubMed ID: 29893302
    [No Abstract]   [Full Text] [Related]  

  • 27. Images in clinical tropical medicine. Multibacillary leprosy in Zambia.
    Zargaran E
    Am J Trop Med Hyg; 2009 Aug; 81(2):189. PubMed ID: 19635867
    [No Abstract]   [Full Text] [Related]  

  • 28. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention.
    Schuring RP; Richardus JH; Pahan D; Oskam L
    Vaccine; 2009 Nov; 27(50):7125-8. PubMed ID: 19786134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-exposure prophylaxis in leprosy (PEOPLE): a cluster randomised trial.
    Hasker E; Assoumani Y; Randrianantoandro A; Ramboarina S; Braet SM; Cauchoix B; Baco A; Mzembaba A; Salim Z; Amidy M; Grillone S; Attoumani N; Grillone SH; Ronse M; Peeters Grietens K; Rakoto-Andrianarivelo M; Harinjatovo H; Supply P; Snijders R; Hoof C; Tsoumanis A; Suffys P; Rasamoelina T; Corstjens P; Ortuno-Gutierrez N; Geluk A; Cambau E; de Jong BC
    Lancet Glob Health; 2024 Jun; 12(6):e1017-e1026. PubMed ID: 38762282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single dose multidrug therapy for single lesion paucibacillary leprosy.
    Porichha D
    Indian J Lepr; 1998; 70(2):213-4; author reply 219-21. PubMed ID: 9724858
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment failure in leprosy.
    Levy L
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):177-82. PubMed ID: 776854
    [No Abstract]   [Full Text] [Related]  

  • 32. Single-dose treatment for single lesion leprosy; histopathological observations.
    Shinde A; Khopkar U; Pai VV; Ganapati R
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):328-30. PubMed ID: 11221099
    [No Abstract]   [Full Text] [Related]  

  • 33. Second coming: the re-emergence and modernization of immunotherapy by vaccines as a component of leprosy control.
    Duthie MS; Casper C; Reed SG
    Future Microbiol; 2018 Oct; 13():1449-1451. PubMed ID: 30311780
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of contact tracing and prevention strategies in the interruption of leprosy transmission.
    Smith WC; Aerts A
    Lepr Rev; 2014 Mar; 85(1):2-17. PubMed ID: 24974438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug therapy regimen for leprosy.
    Firooz A
    J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial: Problems and opportunities in the therapy of leprosy.
    Jopling WH
    Lepr Rev; 1974 Dec; 45(4):285-7. PubMed ID: 4444391
    [No Abstract]   [Full Text] [Related]  

  • 37. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chemotherapy of leprosy. II. Sulfones and sulfonamides].
    Leiker DL
    Ned Tijdschr Geneeskd; 1980 Jan; 124(2):46-8. PubMed ID: 7374822
    [No Abstract]   [Full Text] [Related]  

  • 39. Leprosy in the UK.
    Bharucha T; Lockwood D
    Br J Hosp Med (Lond); 2016 Oct; 77(10):C154-C156. PubMed ID: 27723400
    [No Abstract]   [Full Text] [Related]  

  • 40. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.